FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3156474785> ?p ?o ?g. }

• W3156474785 endingPage "1885" @default.
• W3156474785 startingPage "1874" @default.
• W3156474785 abstract "Abstract Background Current approaches of drug repurposing against COVID-19 have not proven overwhelmingly successful and the SARS-CoV-2 pandemic continues to cause major global mortality. SARS-CoV-2 nsp12, its RNA polymerase, shares homology in the nucleotide uptake channel with the HCV orthologue enzyme NS5B. Besides, HCV enzyme NS5A has pleiotropic activities, such as RNA binding, that are shared with various SARS-CoV-2 proteins. Thus, anti-HCV NS5B and NS5A inhibitors, like sofosbuvir and daclatasvir, respectively, could be endowed with anti-SARS-CoV-2 activity. Methods SARS-CoV-2-infected Vero cells, HuH-7 cells, Calu-3 cells, neural stem cells and monocytes were used to investigate the effects of daclatasvir and sofosbuvir. In silico and cell-free based assays were performed with SARS-CoV-2 RNA and nsp12 to better comprehend the mechanism of inhibition of the investigated compounds. A physiologically based pharmacokinetic model was generated to estimate daclatasvir’s dose and schedule to maximize the probability of success for COVID-19. Results Daclatasvir inhibited SARS-CoV-2 replication in Vero, HuH-7 and Calu-3 cells, with potencies of 0.8, 0.6 and 1.1 μM, respectively. Although less potent than daclatasvir, sofosbuvir alone and combined with daclatasvir inhibited replication in Calu-3 cells. Sofosbuvir and daclatasvir prevented virus-induced neuronal apoptosis and release of cytokine storm-related inflammatory mediators, respectively. Sofosbuvir inhibited RNA synthesis by chain termination and daclatasvir targeted the folding of secondary RNA structures in the SARS-CoV-2 genome. Concentrations required for partial daclatasvir in vitro activity are achieved in plasma at Cmax after administration of the approved dose to humans. Conclusions Daclatasvir, alone or in combination with sofosbuvir, at higher doses than used against HCV, may be further fostered as an anti-COVID-19 therapy." @default.
• W3156474785 created "2021-04-26" @default.
• W3156474785 creator A5000506024 @default.
• W3156474785 creator A5007569728 @default.
• W3156474785 creator A5007635891 @default.
• W3156474785 creator A5008262692 @default.
• W3156474785 creator A5010847795 @default.
• W3156474785 creator A5011090397 @default.
• W3156474785 creator A5015129971 @default.
• W3156474785 creator A5018527455 @default.
• W3156474785 creator A5021304717 @default.
• W3156474785 creator A5024642648 @default.
• W3156474785 creator A5030482883 @default.
• W3156474785 creator A5032988640 @default.
• W3156474785 creator A5033136753 @default.
• W3156474785 creator A5033253153 @default.
• W3156474785 creator A5033987545 @default.
• W3156474785 creator A5034262196 @default.
• W3156474785 creator A5035826389 @default.
• W3156474785 creator A5036531858 @default.
• W3156474785 creator A5042084987 @default.
• W3156474785 creator A5042381817 @default.
• W3156474785 creator A5045550967 @default.
• W3156474785 creator A5046198529 @default.
• W3156474785 creator A5049366282 @default.
• W3156474785 creator A5049963014 @default.
• W3156474785 creator A5050573099 @default.
• W3156474785 creator A5056191252 @default.
• W3156474785 creator A5057369594 @default.
• W3156474785 creator A5059283340 @default.
• W3156474785 creator A5066429649 @default.
• W3156474785 creator A5069412360 @default.
• W3156474785 creator A5074318003 @default.
• W3156474785 creator A5077706769 @default.
• W3156474785 creator A5081350037 @default.
• W3156474785 creator A5081931507 @default.
• W3156474785 creator A5084552494 @default.
• W3156474785 creator A5085160612 @default.
• W3156474785 creator A5085200610 @default.
• W3156474785 creator A5086545337 @default.
• W3156474785 creator A5087557108 @default.
• W3156474785 creator A5089439862 @default.
• W3156474785 date "2021-04-21" @default.
• W3156474785 modified "2023-10-18" @default.
• W3156474785 title "<i>In vitro</i> antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19" @default.
• W3156474785 cites W1979031552 @default.
• W3156474785 cites W2043855224 @default.
• W3156474785 cites W2177685115 @default.
• W3156474785 cites W2572997664 @default.
• W3156474785 cites W2903899730 @default.
• W3156474785 cites W2950382369 @default.
• W3156474785 cites W2952023305 @default.
• W3156474785 cites W2952456408 @default.
• W3156474785 cites W3008443627 @default.
• W3156474785 cites W3009885589 @default.
• W3156474785 cites W3012345473 @default.
• W3156474785 cites W3013893137 @default.
• W3156474785 cites W3015429854 @default.
• W3156474785 cites W3015554176 @default.
• W3156474785 cites W3015708777 @default.
• W3156474785 cites W3016124786 @default.
• W3156474785 cites W3016771699 @default.
• W3156474785 cites W3018023298 @default.
• W3156474785 cites W3020896479 @default.
• W3156474785 cites W3023986730 @default.
• W3156474785 cites W3024057275 @default.
• W3156474785 cites W3026711303 @default.
• W3156474785 cites W3027630905 @default.
• W3156474785 cites W3032677067 @default.
• W3156474785 cites W3041137986 @default.
• W3156474785 cites W3041968020 @default.
• W3156474785 cites W3045003495 @default.
• W3156474785 cites W3092564100 @default.
• W3156474785 cites W3096083800 @default.
• W3156474785 doi "https://doi.org/10.1093/jac/dkab072" @default.
• W3156474785 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8083231" @default.
• W3156474785 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33880524" @default.
• W3156474785 hasPublicationYear "2021" @default.
• W3156474785 type Work @default.
• W3156474785 sameAs 3156474785 @default.
• W3156474785 citedByCount "62" @default.
• W3156474785 countsByYear W31564747852021 @default.
• W3156474785 countsByYear W31564747852022 @default.
• W3156474785 countsByYear W31564747852023 @default.
• W3156474785 crossrefType "journal-article" @default.
• W3156474785 hasAuthorship W3156474785A5000506024 @default.
• W3156474785 hasAuthorship W3156474785A5007569728 @default.
• W3156474785 hasAuthorship W3156474785A5007635891 @default.
• W3156474785 hasAuthorship W3156474785A5008262692 @default.
• W3156474785 hasAuthorship W3156474785A5010847795 @default.
• W3156474785 hasAuthorship W3156474785A5011090397 @default.
• W3156474785 hasAuthorship W3156474785A5015129971 @default.
• W3156474785 hasAuthorship W3156474785A5018527455 @default.
• W3156474785 hasAuthorship W3156474785A5021304717 @default.
• W3156474785 hasAuthorship W3156474785A5024642648 @default.
• W3156474785 hasAuthorship W3156474785A5030482883 @default.
• W3156474785 hasAuthorship W3156474785A5032988640 @default.
• W3156474785 hasAuthorship W3156474785A5033136753 @default.

• next